INTRODUCTION
Epilepsy is common among the learning disabled population, especially those with severe or profound degree, of learning disabilities'.
It is estimated that in the community there are at least 1600 people per million with both epilepsy and learning disability' and up to 44% of these people are in touch with secondary services. A survey of all the severely learning disabled children originating from the London borough of Camberwell" showed that: one third of these children had experienced seizures at some time and one fifth had at least one seizure in the year before the enquiry; the risk of seizure disorder increases with the severity of learning disability; where postnatal injury is a factor in causing a severe degree of learning disabilities, epilepsy is virtually inevitable; for many, epilepsy may persist well into their adult life; the prevalence of epilepsy appears to be more common amongst boys when compared to that of girls. These findings were confirmed by Richardson ef alJ.
A substantial proportion of patients with learning disabilities and epilepsy continue to suffer from poorly-controlled seizures despite the use of two or more antiepileptic drugs (AEDs)'. The situation is further complicated by the complex interactions between the multiple needs of these individuals. Many suffering from drugresistant epilepsy not only suffer from severe or profound degrees of learning disabilities but also have associated secondary handicaps including increased susceptibilty to physical illness, constipation and infectionh. They are frequently on more than one AED and both drug interactions and side-effects are problematic.
In addition there are often difficulties in assessing drug side-effects, including the effect of the medication on cognitive functioning, because of concurrent cognitive impairment.
Many adults with learning disabilities and epilepsy suffer from more than one seizure type 0 1997 British Epilepsy Association although the nature of the seizures may be similar to those suffered by non-learning disabled epileptics. In addition there may also be the problem of an associated behaviour disorder/psychiatric disorder',*. It is possible to classify the seizure disorders occurring in these individuals by its phenomenology although history may need to be supplemented by EEG studies'. In one large study a precise diagnosis could only be determined in 34% of all people suffering from epilepsy who attended a general practice clinic". EEG studies can occasionally present with difficulties in some of the patients belonging to this group, especially because of the lack of understanding and the lack of co-operation in going through such a procedure. Similar problems might be encountered in further investigations such as CT head scan or MRI scan. It is acknowledged that in the epileptic population with learning disabilities a substantial proportion of patients also experience pseudo-seizures. However, the extent of this problem and the prevalence of it is, as yet, unclear compared to that of the general population.
The drug treatment of epilepsy in people with learning disabilities has previously been confined to the use of AEDs such as sodium valproate, carbamazepine, phenytoin or benzodiazepines including clobazam and clonazepam. The seizure disorder in the majority of the patients is well controlled with the use of one AED or, at best, a combination of two. However, a substantial minority of patients do continue to suffer from seizures despite the use of two or more drugs and it is this group of patients who are likely to benefit from the use of a newer AED. Until the recent introduction of three new AEDs (vigabatrin, lamotrigine and gabapentin) the treatment of poorly controlled epilepsy has been limited to adjusting doses of a handful of older AEDs. Reducing the number of AEDs taken by individual patients tends to reduce adverse events but can lead to an increase in seizure frequency".
The introduction of vigabatrin, lamotrigine and gabapentin has increased the choice of this area of drug treatment but has it increased the likelihood of a reduction in seizures? Very few studies have been carried out on patients with learning disabilities suffering from poorly controlled epilepsy. In a study of the antiepileptic efficacy of vigabatrin'* in 36 patients with learning disabilities and drug-resistant epilepsy, 43% of the patients with seizures of partial onset and 33% of the patients with primary generalized seizures showed more than 50% reduction in seizure frequency during a 7-seven month follow-up period. Twenty-two adult patients with learning disabilities were treated in an open trial with vigabatrin I3 Forty-five per cent showed a . reduction in seizure frequency of more than 50%. Adverse events were reported in 20 of the 22 patients during the 64 week study period, the most frequently reported adverse events being sedation, aggression, agitation and ataxia. Other clinical trials that have included patients with learning disabilities were a study of lamotrigine in 120 children14, 62% of whom suffered from learning disabilities, and a three-cohort study of vigabatrin one cohort of which was 36 learning disabled patients with severe epilepsy". Both clinical trials demonstrated similar efficacy to those by others'2.'3.
Our study is a naturalistic study. We reviewed the first 51 patients prescribed vigabatrin, lamotrigine and gabapentin.
All were adults with learning disabilities suffering from refractory epilepsy, the aim being to compare the efficacies, adverse events and drop-out rates for all three drugs.
MATERIALS AND METHODS
The case lists of the four consultant psychiatrists employed by the Glenfrith Division of Fosse Health Trust were examined in order to identify those patients prescribed either vigabatrin, lamotrigine or gabapentin. For each patient prescribed any of the three new AEDs within the period 1991-1995, a retrospective casenote analysis was undertaken.
Information was gathered and comparisons were made between the three treatment groups of vigabatrin, lamotrigine and gabapentin regarding age, sex, residence, degree of learning disabilities, cause of primary handicap, age of onset of epilepsy, AEDs prescribed prior to prescribing the new drugs, current AEDs, seizure frequency prior to and after add-on therapy, any side-effects reported, and drop-out rates including reasons for dropout. The data was collected and analysed using SPSS.
RESULTS
The study of 51 casenotes revealed 71 occasions, during the previous 4 years, when patients were prescribed either vigabatrin, lamotrigine or gabapentin. As some patients were treated with more than one newer AED, the calculations were made in terms of treatment episodes. Twenty-three treatment episodes were identified with vigabatrin, 25 with lamotrigine and 23 with gabapentin. In the vigabatrin group 12 patients were treated with vigabatrin alone. Similarly, 10 patients were treated with lamotrigine alone in the lamotrigine group. In the gabapentin group there were 10 individuals who were treated with gabapentin alone. There were altogether three individuals who were tried with all three newer AEDs in succession and there were 16 patients who were treated with two of the newer drugs out of three. Twenty-eight patients were male and 23 female. The mean age for males was 39 years (range, 21-54 years) and for females 38 years (range, 20-66 years). The age and sex distribution between the three groups were found to be very similar. The mean age for patients treated with vigabatrin, lamotrigine and gabapentin was noted to be 39 f 10 years, 36 f 9 years and 37 f 9 years, respectively.
Epilepsy had been diagnosed in most patients in childhood and all patients had other disabilities in addition to epilepsy. The age of onset of epilepsy ranged from 6 weeks to 49 years, with 96% suffering from epilepsy before the age of 5 years.
Despite suffering from refractory epilepsy, most patients were living in the community: 23 (45%) were living with parents or relatives, 11 (22%) were living in hostels and the remainder lived in hospital.
The causes of the learning disabilities were known or suspected in 50% of the patients and included conditions such as cerebral palsy, meningitis, congenital brain malformations and perinatal brain damage. Cerebral palsy and meningitis/encephalitis appeared to be the most common causes of learning disabilities. Although the distribution of the causes of learning disability were similar for those treated with either vigabatrin, lamotrigine or gabapentin, there were some differences between the treatment groups (see Table 1 ).
An assessment of the degree of learning disability was carried out. The patients spanned all levels of ability (10 mild, 15 moderate, 18 severe and eight profoundly learning disabled). Although more of those with mild learning disabilities and fewer of those with profound learning disability were female, the distribution of degree of learning disabilities by gender was similar. Although the distribution of degree of learning disabilities was found to be broadly similar in the three treatment groups, more patients with severe learning disabilities received lamotrigine and gabapentin compared to that of vigabatrin (see Table 2 ).
The main seizure type suffered by the patients was noted to be primary generalized (n = 37, 73%). The remainder suffered from complex partial seizures and partial seizures, with or without secondary generalization.
Twenty-eight patients (61%) suffered from one seizure type with 15 (29%) suffering from two seizure types and eight (10%) suffering from three or more seizure types. There was little difference between the type of seizures suffered by the patients in three treatment groups.
The seizure frequency prior to treatment with newer AEDs was found to be very similar in all the three treatment groups with a median seizure frequency of 5-10 seizures per month and the range of the frequency being a minimum of l-5 seizures per month, maximum up to more than 30 seizures per month.
Twenty-five percent of the patients prior to treatment with newer AEDs were prescribed only one AED and 50% prescribed two AEDs, with the remaining 25% of the patients receiving three AEDs or more. Most patients had previously received carbamazepine or sodium valproate with the individual drug use of carbamazepine 39, sodium valproate 26, phenytoin 13, clonazepam 12, phenobarbitone 7, clobazam 4, primidone 2, ethosuximide 1 patient, respectively. The high prescribing rate for drugs such as phenytoin, phenobarbitone and primidone is more related to the refractory nature of the epilepsy in these cases than their general use. There was little difference between the treatment groups in respect of the number of AEDs they had been taking prior to treatment with the newer AEDs. The doses and duration of treatment with the three new AEDs are provided in Table 3 , whereas Table 4 shows the relative efficacy of the three newer drugs in the reduction of seizures. All three drugs appear to have similar efficacies, with 36% to 56% of patients benefiting from a seizure reduction of more than 50%. It was interesting to note that 26% of patients on vigabatrin became seizure-free compared to only 4% for gabapentin and none for lamotrigine.
Seizure-free 6(26%) 0 (0%) 1 (4%) Side-effects 9 (39%) 7(28%) 6(26%) Increased seizures 2 (8%) 6 (24%) 0 (0%) N.B. Some patients received treatment with more than one newer AED.
DISCUSSION
Although more side-effects were reported by patients on vigabatrin rather than lamotrigine and gabapentin, this was not statistically significant (P = 0.58). It was surprising to note that 24% of patients on lamotrigine suffered from increased seizures compared to 8% for vigabatrin and none in the gabapentin group.
When discontinuation of the newer AED occurred it was either due to side-effects, lack of effect or increased seizures. Table 5 examines the reason for discontinuation.
All three drugs appeared to be very similar in the reasons for discontinuation.
Although fewer patients on gabapentin discontinued due to side-effects, this is not statistically significant.
The problem in carrying out a clinical drug trial in the field of learning disabilities is well known and includes many ethical and consent issues. There is also the associated problem of high extent of polypharmacy and other co-existing physical and mental health problems which tend to exclude many patients from the clinical drug trials. This study has the strength of being naturalistic
and therefore reflected what happened in real clinical practice as there were no exclusion criteria. However, it has its limitations of being a retrospective casenote analysis and therefore caution should be exercised in drawing definitive conclusions. Table 6 shows the prevalence of reported side-effects with each drug. In the vigabatrin group increased behaviour problems was the most common side-effect encountered. However, two patients in the lamotrigine group and one patient in the gabapentin group suffered similar problems. Three patients on lamotrigine suffered rashes which did not occur with the other two drugs. Drowsiness and unsteady gait were the main side-effects reported with gabapentin.
Patients who continue to suffer from seizures despite adequate drug treatment remain a challenging group for the medical profession. The introduction of new AEDs offers hope for patients with epilepsy who remain refractory to medical treatment. This study suggests that all the three new AEDs (vigabatrin, lamotrigine and gabapentin) can be effective add-on treatment for poorly controlled epilepsy in patients with learning disabilities but that only 30-50% of the patients are likely to benefit from such treatment. It is clear that in this study the clinicians did not prescribe the newer AEDs within their data sheet indication and the reasons for choosing one particular new AED in each particular case appeared to have been determined by chronolog- ical availability of the newer drugs rather than anything else; nevertheless, there are some indications that some of the newer drugs, e.g. lamotrigine and gabapentin, may be effective in controlling refractory primary generalized seizures as well. In this study gabapentin was the most successful AED in achieving a more than 50% seizure reduction despite the fact that the dosage used was only up to the recommended limit at that time. Increasingly, more evidence is coming out that gabapentin is likely to achieve better seizure control at a much higher dose level than that which was previously recommended. However, it was interesting to note that 26% of patients with vigabatrin became seizure-free, compared to only 4% of patients with gabapentin and none with lamotrigine.
although overall all three drugs were similar in their performance. appeared to be the drug with fewer interactional problems and better side-effect profile when compared to the other two groups of drugs, the small numbers involved in this study made these findings difficult to generalize. The overall discontinuation rates in three different groups appear to be very similar, with the lowest rate being noted in the gabapentin group. However, this finding could be challenged because patients are likely to have received gabapentin for a shorter period of time as it is the most recently available of the three drugs. Recent reports, however, have suggested that gabapentin, if well tolerated, can be used in a much higher dose than the recommended at present and at the higher dose range it is likely to achieve more benefit.
The problem of increased seizures with drug treatment with newer AEDs has not been researched adequately and it was striking to note that 24% of patients on lamotrigine suffered from increased seizures. This development of increase of seizures appeared to be linked with the use of a higher dose of lamotrigine. None of the patients on gabapentin suffered from any increased seizures..
The adverse events noted for each drug are very similar to those of previous reviews"'. However, it was interesting to note that increased behaviour problems (though most frequently encountered with vigabatrin) were not confined to that drug alone. Although gabapentin
The study identified several specific issues related to epilepsy in the learning disabled population. The interactions between physical, social and psychological problems in individuals suffering from epilepsy and learning disability are complex and their impact on the patient and his/her carers can influence the outcome of any medical interventions. Moreover, many learningdisabled patients suffer from compromised renal/hepatic functions and may also suffer from increased susceptibility to infections, constipation etc. which can influence AED therapy and effective seizure control adversely. There is also an increased prevalence of polypharmacy and associated problems of drug interactions and it is worthwhile to bear in mind that many patients are on additional psychotropic medication for their associated behaviour problems or psychiatric disorders which are likely to influence their seizure threshold. Any impact of AED therapy on an individual has to be assessed globally. including the impact of the medication on the individual's cognitive functions. The majority of the patients with learning disabilities have already somewhat compromised cognitive functions and any further deterioration of the cognitive functions can cause a dramatic deterioration in their quality of life. Caring for individuals with learning disabilities and epilepsy for a life time can be quite stressful for the carers and it is imperative that the clinicians dealing with such individuals should pay due attention to carer stress and the associated family dynamics. Furthermore, some individuals suffer from progressive neurodegenerative conditions, for example Rett's Syndrome, where heroic attempts to control and reduce the seizure frequency can lead to a disastrous impact on the patient's quality of life and thereby cause more distress. In general it is important to bear in mind that in dealing with a patient with learning disability suffering from refractory epilepsy, a global assessment is imperative and any intervention plan is to be discussed in detail including the associated risks and benefits with the carers and individual concerned, where possible. When a newer AED treatment is initiated, clinicians should maintain regular contact with the family/carers and a slow, gradual, introduction of the newer drug is highly preferable than the introduction plan suggested by most of the data sheets. This is helpful, not only in avoiding side-effects, but also in avoiding any compliance problems. In assessing patients with epilepsy, the primary factor has conventionally been the reduction or abolition of seizures. However, this represents a rather simplistic approach. Seizure frequency may vary spontaneously and the seizure number does not wholly reflect disability since the severity of the seizure is ignored and associated psychological issues are not addressed. In addition, social aspects should ideally be taken into account. Any adverse event, when it arises, can cause distress in the individual concerned and also for the carers and opportunities should exist for them to contact the clinician immediately for advice and support. The drop-out rates can be minimized by such a carefully laid out plan. which enhance independence are needed to be taken into account when considering the impact of any drug treatment of epilepsy in individuals with learning disabilities. A long-term prospective study using the newer drugs in an open-ended trial in adults with learning disabilities suffering from refractory epilepsy will clarify these issues and might help us to identify the likely responders and also to select specific newer AEDs for individual patients. There is little doubt that, in some patients, these newer agents can have a major impact both on crude seizure rate and the quality of life. However, there will remain a sub-group of patients whose seizures will fail to respond or in whom the quality of life will be poor for reasons beyond the control of the caring professionals.
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It appears that the newer AEDs are likely to play a positive role in the control of epilepsy and improvement in the quality of life for some patients with learning disabilities suffering from drug-resistant epilepsy. However, to clarify the issues further, one needs to look at the long-term efficacy of these newer AEDs and also their effects on cognitive functioning of individuals. The avoidance of use of unnecessary polypharmacy, correct medical treatment of the epilepsy, recognition and avoidance of drug side-effects and other social and psychological measures 8.
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